Kate Burba

Tirzepatide 15 mg produced similar weight loss results as bariatric surgery among patients with obesity but had a favorable safety profile, according to a presenter at the ACG Annual Scientific Meeting.

Video Player is loading. Play Video Play Mute Current Time Duration

SAN DIEGO — Preemptive continuous renal replacement therapy after therapeutic plasma exchange reduced mortality and improved other outcomes in

SAN DIEGO — Retreatment with nucleos(t)ide analogue therapy for relapse after withdrawal did not affect hepatitis B surface antigen seroclearance

SAN DIEGO — Increasing the mean arterial pressure target to 75 mmHg lowered the odds of 28-day mortality by 85%, and also reduced the odds of acute

SAN DIEGO — Once-daily FXR314 was well-tolerated and safely improved liver fat content and biochemical markers over 16 weeks in patients with

SAN DIEGO — Treatment with combination tobevibart and elebsiran led to hepatitis B surface antigen loss among 39% of patients with chronic HBV and

Key takeaways: Results showed 41% of patients achieved HDV target not detected at week 24.

Key takeaways: HBV-infected children treated with combination PEG-INF a-2b/nucleos(t)ide analogues achieved higher HBsAg loss rates vs. monotherapy.

SAN DIEGO — Treatment with glucagon-like peptide-1 receptor agonists significantly reduced alanine aminotransferase among children with metabolic